RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: baseline and follow-up [Ga]Ga-PSMA-11 PET/CT was analysed
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Registered 11 June 2015. Retrospectively registered.
[PURPOSE] Up to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited.
- p-value p < 0.001
- 95% CI 2.41-8.87
APA
Molin K, Ong JSL, et al. (2026). RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.. European journal of nuclear medicine and molecular imaging, 53(4), 2234-2244. https://doi.org/10.1007/s00259-025-07592-6
MLA
Molin K, et al.. "RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.." European journal of nuclear medicine and molecular imaging, vol. 53, no. 4, 2026, pp. 2234-2244.
PMID
41145918 ↗
Abstract 한글 요약
[PURPOSE] Up to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited. This study compared Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) and PSMA PET Progression (PPP) criteria in predicting overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). As a secondary aim, PROMISE-based nomograms were assessed as tools for OS prediction.
[METHODS] A cohort of 154 BCR PCa patients with baseline and follow-up [Ga]Ga-PSMA-11 PET/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan-Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.
[RESULTS] RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41-8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.
[CONCLUSION] In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification.
[TRIAL REGISTRATION NUMBER] ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.
[METHODS] A cohort of 154 BCR PCa patients with baseline and follow-up [Ga]Ga-PSMA-11 PET/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan-Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.
[RESULTS] RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41-8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.
[CONCLUSION] In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification.
[TRIAL REGISTRATION NUMBER] ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.